Lanean...
Necdin modulates leukemia-initiating cell quiescence and chemotherapy response
Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that...
Gorde:
| Argitaratua izan da: | Oncotarget |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Impact Journals LLC
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5675657/ https://ncbi.nlm.nih.gov/pubmed/29152105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20999 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|